Keiretsu Capital’s Post

Viridian Therapeutics announced positive topline data from its phase 3 THRIVE clinical trial (NCT05176639) of veligrotug, previously known as VRDN-001, in patients with active thyroid eye disease (TED). Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.” Furthermore, THRIVE met both the primary and all secondary endpoints at 15 weeks after 5 infusions of veligrotug. Additionally, veligrotug showed a rapid onset of action, with the majority (53%) of veligrotug-treated patients achieving a proptosis response after just 1 infusion, or 3 weeks after the start of therapy. Read more: https://lnkd.in/e6j5AZih

BiPER Therapeutics raises €800k in bridge funding to advance its first-in-class BiP-inhibitor for gastrointestinal cancers to clinical trials https://lnkd.in/eWNFhXFm BiPER Therapeutics WiSEED Bpifrance Mathilde Iclanzan Mehdi Chelbi Morgan Rapinat More French life science business news at [LSF] Life-Sciences-France.com __

I will present this webinar tomorrow along with Dr. Michelle Becker, pharmacist specialized in IBD medication management. We have a lot of insights to offer. Join us online to learn more!

Kidney Awareness Month during March is a particularly meaningful time for us here at Memo Therapeutics, given the many challenges facing Chronic Kidney Disease (#CKD) patients, especially those needing kidney transplantation. With approximately 500,000 people requiring end stage renal disease dialysis support and 100,000 people waiting for kidney transplants in the US alone, early diagnosis and pre-emptive treatment could save thousands of patients’ lives and preserve the quality of life for many others. At Memo Therapeutics, we have used our innovative antibody discovery platform to develop a monoclonal antibody, now in Phase II clinical development, to target BK virus: a major contributor to post-transplantation complications and ultimately graft loss. Read more about our program here:  https://lnkd.in/en6ZhHbV #KidneyAwarenessMonth #KidneyHealth #TransplantsforAll #MemoTherapeutics #MTx #Biotech #AntibodyDiscovery #InfectiousDiseases #DrugDiscovery  

Abbisko Therapeutics (SEHK:2256), a portfolio company of Qiming Venture Partners, announced that its co-developed Fibroblast Growth Factor 19 (FGF19) antibody reagent has obtained the registration testing report. This antibody reagent has undergone comprehensive research for its application in hepatocellular carcinoma (HCC), demonstrating exceptional specificity, sensitivity, and stability. The reagent will play a key role in the pivotal clinical trials for Abbisko Therapeutics' novel small-molecule FGFR4 inhibitor, Irpagratinib (ABSK011). #BiotechInnovation #LiverCancer #Immunotherapy #HealthcareAdvancement #MedicalResearch #ClinicalTrials #PharmaceuticalResearch #CancerTreatment #QimingPortfolio #QimingHealthcare

NX-1607: FIRST-IN-CLASS SMALL MOLECULE INHIBITOR OF CBL-B IN THE IMMUNO-ONCOLOGY FIELD Recurrent diffuse large B cell lymphoma (DLBCL) remains a high unmet medical need despite advances in treatment such as cell- and immune-mediated therapies. Based on United States (U.S.) cancer registry data, age-standardized incidence rate for DLBCL was 7.2 per 100,000. DLBCL incidence rises with age and is generally higher in males than females; in the U.S., incidence is highest among non-Hispanic whites (9.2/100,000). The emergence of resistance to current therapies, including to T cell-mediated therapies such as CAR-T and T cell engagers underscores the need for novel therapies that can enhance T cell function, counteract a suppressive tumor microenvironment (TME) and prevent tumor escape associated with low tumor antigen expression. Casitas B-lineage lymphoma proto-oncogene B (CBL-B) is an E3 ubiquitin ligase expressed in immune cells and is a master regulator of T, NK, and dendritic cell activation, collectively curtailing their anti-tumor functionality. NX-1607 is an oral, first-in-class small molecule inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for immuno-oncology, that has been shown to enhance antigen recall, reduce T cell exhaustion and increase cytokine production upon T cell receptor stimulation, overcoming suppressive signals from the TME. Moreover, preclinical studies in mouse lymphoma models have demonstrated that NX-1607 can induce robust, T cell-dependent tumor regression. By bolstering the effectiveness of inherent T- and NK-mediated anti-tumor responses and enhancing antigen recall, NX-1607 offers potential as a supportive and rejuvenating agent for CAR-T or NK cell therapies in patients with hematologic malignancies who have developed resistance. Here, a real med chem tour-de-force from Frederick Cohen and the talented Nurix Therapeutics team. #NX_1607 #immuno_oncology #DLBCL. Reported by https://lnkd.in/dckZk78C

🏆Congratulations to our partners at Ascentawits Pharma for receiving the "Outstanding Paper Award" at CSCO! OBI Pharma's partner, Ascentawits Pharma Ltd., presented promising interim results for AST-3424 (OBI-3424) at #CSCO2024: Phase II study in advanced hepatocellular carcinoma (HCC) Median OS: 10.8 months (12.3 months for 2nd line+) ORR: 6.7%, DCR: 60.0% Potential new option for late-line HCC patients Key highlights: ✅ Encouraging survival benefits ✅ Good safety profile ✅ Effective in patients who progressed after immunotherapy AST-3424, a first-in-class AKR1C3-activated prodrug developed by OBI Pharma, shows promise for HCC patients with limited options. OBI Pharma continues to collaborate closely with Ascentawits through the sharing of clinical data and information. #OBI3424 #CancerResearch #ClinicalTrials #LiverCancer #Partnership https://lnkd.in/gEd4bubg

On World Lung Cancer Day, we honor the resilience of those affected by lung cancer and their loved ones. At Bonita Pharmaceuticals, we are dedicated to supporting research, and access to essential treatments. Together, we can make a difference in early detection and treatment. #worldlungcancerday #bonitapharmaceuticals #cancerawareness #lungcancer #support #healthcareheroes #bonitapharma #pharmacydeals #savebig #trustedpharma #pharmaceuticals #westlandmi #healthcareforyou #drugstore #medicine #distributor #medications #genericdrugs #independentpharmacy

Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma.Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor. In 2018, toripalimab was approved in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy. In October 2023, the US Food and Drug Administration (FDA) approved toripalimab for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma when used with cisplatin and gemcitabine.

Looking forward to clinical readouts in multiple cancer indications in coming months